Guardant Health Inc.(GH),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

GH Guardant Health Inc.

Not Yet Opened 06-09 16:00:00 EDT

130.12

+5.23

+4.19%

盘后130.13

+0.01+0.01%

19:50 EDT

High130.36	Low122.76	Vol2.26M
Open125.27	D1 Closing124.89	Amplitude6.09%
Mkt Cap17.25B	Tradable Cap16.53B	Total Shares132.57M
T/O287.34M	T/O Rate1.78%	Tradable Shares127.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"GH","market":"US","secType":"STK","nameCN":"Guardant Health Inc.","latestPrice":130.12,"timestamp":1781035200000,"preClose":124.89,"halted":0,"volume":2258295,"hourTrading":{"tag":"盘后","latestPrice":130.13,"preClose":130.12,"latestTime":"19:50 EDT","volume":70610,"amount":9216741.48,"timestamp":1781049059441,"change":0.01,"changeRate":0.000077,"amplitude":0.000077},"delay":0,"changeRate":0.041876851629433935,"floatShares":127000000,"shares":132573424,"eps":-3.404949,"marketStatus":"Not Yet Opened","change":5.23,"latestTime":"06-09 16:00:00 EDT","open":125.27,"high":130.36,"low":122.76,"amount":287337958.26060003,"amplitude":0.060854,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.404949,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1781078400000},"marketStatusCode":0,"adr":0,"adrRate":0,"listingDate":1538625600000,"exchange":"NASDAQ","adjPreClose":124.89,"preHourTrading":{"tag":"盘前","latestPrice":126.0792,"preClose":124.89,"latestTime":"08:56 EDT","volume":176,"amount":22254.31472,"timestamp":1781009764325,"change":1.1892,"changeRate":0.009522,"amplitude":0.061812},"postHourTrading":{"tag":"盘后","latestPrice":130.13,"preClose":130.12,"latestTime":"19:50 EDT","volume":70610,"amount":9216741.48,"timestamp":1781049059441,"change":0.01,"changeRate":0.000077,"amplitude":0.000077},"volumeRatio":0.95895,"impliedVol":0.544,"impliedVolPercentile":0.1594},"requestUrl":"/m/hq/s/GH","defaultTab":"news","newsList":[{"id":"2642448857","title":"Do GH Research’s (GHRS) Phase 2a Postpartum Data Subtly Reframe Its Broader Depression Strategy?","url":"https://stock-news.laohu8.com/highlight/detail?id=2642448857","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642448857?lang=en_us&edition=fundamental","pubTime":"2026-06-10 13:13","pubTimestamp":1781068399,"startTime":"0","endTime":"0","summary":"GH Research PLC recently reported full peer-reviewed results from its Phase 2a open-label trial of inhaled Mebufotenin (GH001) in postpartum depression, showing rapid remission on the MADRS scale, improved maternal functioning, and a favorable tolerability profile, and confirmed that two GH001 depression data sets were accepted for oral presentation at the 37th World Congress of Neuropsychopharmacology in Glasgow later this month.\nAn additional practical insight for clinicians and patients...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ghrs/gh-research/news/do-gh-researchs-ghrs-phase-2a-postpartum-data-subtly-reframe","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ghrs/gh-research/news/do-gh-researchs-ghrs-phase-2a-postpartum-data-subtly-reframe","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["GHRS","BK4007","BK4551","BK4539","BK4196","BK4535","BK4585","GH","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642432009","title":"Guardant Health Co-CEO Helmy Eltoukhy disposes of common shares worth $12.54 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2642432009","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642432009?lang=en_us&edition=fundamental","pubTime":"2026-06-09 06:30","pubTimestamp":1780957804,"startTime":"0","endTime":"0","summary":"Guardant Health co-Chief Executive Officer Helmy Eltoukhy reported sales of 100,000 common shares on June 5, 2026.Sales were executed at weighted average prices between USD 125.57 and USD 132.55 per share.Holdings in the Helmy A. Eltoukhy Revocable Trust fell to 2,012,919 shares following the transactions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guardant Health Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 08, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260608:nNDL6VwSRN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4551","GH","BK4588","BK4535","BK4196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642320664","title":"Guardant Health CFO Michael Brian Bell disposes of 2,000 common shares worth $257,240.60","url":"https://stock-news.laohu8.com/highlight/detail?id=2642320664","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642320664?lang=en_us&edition=fundamental","pubTime":"2026-06-09 06:29","pubTimestamp":1780957777,"startTime":"0","endTime":"0","summary":"Guardant Health CFO Michael Brian Bell sold 2,000 common shares on June 5, 2026 at USD 128.62 each.Bell’s direct stake fell to 47,509 shares following the transaction.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guardant Health Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 08, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260608:nNDL3X0TJS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Guardant Health CFO Michael Brian Bell disposes of 2,000 common shares worth $257,240.60","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4551","BK4588","BK4196","BK4535","GH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641921486","title":"Guardant Health Inc : Mizuho Raises Target Price to $175 From $135","url":"https://stock-news.laohu8.com/highlight/detail?id=2641921486","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641921486?lang=en_us&edition=fundamental","pubTime":"2026-06-08 19:01","pubTimestamp":1780916507,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260608:nFWN42G0DL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4535","GH","BK4551","BK4196","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641123435","title":"Guardant Health director Steve Krognes disposes of 9,294 common shares worth $1.23 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2641123435","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641123435?lang=en_us&edition=fundamental","pubTime":"2026-06-06 07:51","pubTimestamp":1780703466,"startTime":"0","endTime":"0","summary":"Guardant Health director Steve E. Krognes sold 9,294 common shares on June 4, 2026 at a weighted average price of USD 132.51.His direct holdings fell to 10,222 shares following the sale.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guardant Health Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 05, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260605:nNDL7RnDRs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Guardant Health director Steve Krognes disposes of 9,294 common shares worth $1.23 million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4535","BK4196","BK4588","GH","BK4551"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641110162","title":"Guardant Health Initiated at Buy by Goldman Sachs","url":"https://stock-news.laohu8.com/highlight/detail?id=2641110162","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641110162?lang=en_us&edition=fundamental","pubTime":"2026-06-05 20:08","pubTimestamp":1780661280,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/GH/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 05, 2026 08:08 ET (12:08 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2471134523.USD","LU2471134952.CNY","IE00BFXG1179.USD","IE00BSNM7G36.USD","BK4516","BK4533","LU0868494708.USD","LU1868836591.USD","LU2237443978.SGD","LU0048573561.USD","LU0251131958.USD","LU0345770993.USD","LU2237443895.HKD","LU2237443465.HKD","LU2750360997.AUD","GH","LU0106831901.USD","LU2237443622.USD","IE0002270589.USD","LU2237438978.USD","LU1868836914.USD","LU1868837136.USD","BK4588","BK4552","LU2471134879.HKD","LU0345770308.USD","BK4585","BK4196","LU0096364046.USD","LU0251142724.SGD","LU1804176565.USD","BK4535","LU0061475181.USD","LU1894683348.USD","LU1868837300.USD","IE0034235188.USD","LU0942090050.USD","BK4504","LU2265009873.SGD","LU2237443382.USD","LU0742534661.SGD","LU1868836757.USD","BK4551","IE0004086264.USD","LU1791807156.HKD","LU1668664300.SGD","LU1894683264.USD","IE0004091025.USD","BK4127","GSX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641011507","title":"Guardant Health initiated with a Buy at Goldman Sachs","url":"https://stock-news.laohu8.com/highlight/detail?id=2641011507","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641011507?lang=en_us&edition=fundamental","pubTime":"2026-06-05 16:35","pubTimestamp":1780648520,"startTime":"0","endTime":"0","summary":"Goldman Sachs initiated coverage of Guardant Health (GH) with a Buy rating and $165 price target The company has seral near term growth drivers, in...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/guardant-health-initiated-with-a-buy-at-goldman-sachs-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/guardant-health-initiated-with-a-buy-at-goldman-sachs-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2237443895.HKD","LU2237443622.USD","LU2750360997.AUD","BK4516","BK4196","BK4585","LU1791807156.HKD","LU0048573561.USD","LU0251131958.USD","LU2471134523.USD","LU2237443465.HKD","LU2471134952.CNY","LU1868837136.USD","LU1804176565.USD","BK4588","IE0034235188.USD","LU0345770308.USD","LU1868836591.USD","LU0345770993.USD","GH","LU2237438978.USD","IE0004086264.USD","LU0096364046.USD","LU0061475181.USD","BK4127","LU1868837300.USD","LU2237443382.USD","LU2750360641.GBP","BK4552","LU2237443549.SGD","GSX","BK4533","BK4504","LU0868494617.USD","IE00B19Z3B42.SGD","BK4550","IE0002270589.USD","BK4551","LU0868494708.USD","LU0742534661.SGD","LU0251142724.SGD","LU2237443978.SGD","LU1894683348.USD","LU2471134879.HKD","IE0004091025.USD","IE00BFXG1179.USD","IE00BSNM7G36.USD","LU1868836757.USD","LU0106831901.USD","LU0942090050.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641191043","title":"Leerink Partners Reaffirms Their Buy Rating on Guardant Health (GH)","url":"https://stock-news.laohu8.com/highlight/detail?id=2641191043","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641191043?lang=en_us&edition=fundamental","pubTime":"2026-06-05 11:35","pubTimestamp":1780630539,"startTime":"0","endTime":"0","summary":"Leerink Partners analyst Puneet Souda reiterated a Buy rating on Guardant Health on June 2. The company’s shares closed yesterday at $130.17. Accor...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/leerink-partners-reaffirms-their-buy-rating-on-guardant-health-gh-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/leerink-partners-reaffirms-their-buy-rating-on-guardant-health-gh-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641108160","title":"Guardant Health director Meghan Verena Joyce reports disposal of common shares worth $1.27 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2641108160","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641108160?lang=en_us&edition=fundamental","pubTime":"2026-06-05 06:08","pubTimestamp":1780610910,"startTime":"0","endTime":"0","summary":"Guardant Health director Meghan Verena Joyce reported option exercises on June 3, 2026, acquiring 10,000 shares at USD 38.42 and USD 38.01.She reported same-day sales totaling 10,000 shares at weighted average prices of about USD 126.52 to USD 129.31.Her direct holdings stood at 11,183 shares following the transactions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guardant Health Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 04, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260604:nNDL19zTZH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Guardant Health director Meghan Verena Joyce reports disposal of common shares worth $1.27 million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GH","BK4535","BK4196","BK4588","BK4585","BK4551"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641641771","title":"A new blood test can help detect colon cancer, but it's not as good as the test you hate to take","url":"https://stock-news.laohu8.com/highlight/detail?id=2641641771","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641641771?lang=en_us&edition=fundamental","pubTime":"2026-06-05 03:39","pubTimestamp":1780601940,"startTime":"0","endTime":"0","summary":"The symptoms of colon cancer are often silent, and colonoscopies can prevent and detect colon cancer. The American Cancer Society recently recommended that two blood tests can be an option for people who won't get a colonoscopy or do a stool test.No one looks forward to a colonoscopy, but for the millions of Americans who refuse screening, a simple blood test could help catch colon cancer.For the first time, the American Cancer Society recommended in an announcement last month that a blood test could be used to screen people who choose not to or can't get a colonoscopy.However, the test is far less effective than a colonoscopy, which is the gold standard in preventing and detecting colon cancer, or a stool test, which was made popular over the past decade by the humorous ad blitz created by Exact Sciences, the developer of the Cologuard stool test.The good news is that there is now a wider range of testing options to ensure that more Americans are getting tested for colon cancer. But s","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1057294990.SGD","LU0289739699.SGD","LU2089984988.USD","SGXZ23171101.USD","IE0002141913.USD","LU0122379950.USD","BK4551","BK4196","LU0058720904.USD","BK4082","LU0868494617.USD","LU2211815571.USD","LU0266013472.USD","SG9999002224.SGD","BK4588","LU0234572021.USD","LU2324357040.USD","GH","LU0114720955.EUR","IE00BJJMRZ35.SGD","LU1691799644.USD","BK4566","LU2468319806.SGD","LU0170899867.USD","LU1721429741.USD","BK4533","BK4585","IE00BJT1NW94.SGD","BK4504","LU1989763427.SGD","LU2112291526.USD","BK4535","LU2237957902.USD","ABT","LU1914381329.SGD","LU0882574055.USD","LU2237957811.SGD","LU1989763690.USD","IE0009355771.USD","BK4592","SG9999004303.SGD","SGXZ41872573.SGD","LU1023059063.AUD","LU1061106388.HKD","LU1721429402.USD","IE00B4R5TH58.HKD","BK4568","BK4581","SG9999002232.USD","LU2133065610.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640165363","title":"GH Research announces publication of Phase 2a results for mebufotenin","url":"https://stock-news.laohu8.com/highlight/detail?id=2640165363","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640165363?lang=en_us&edition=fundamental","pubTime":"2026-06-04 22:40","pubTimestamp":1780584034,"startTime":"0","endTime":"0","summary":"GH Research (GHRS) announced the publication of the full results from its Phase 2a trial in postpartum depression and the acceptance of two oral pr...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/gh-research-announces-publication-of-phase-2a-results-for-mebufotenin-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/gh-research-announces-publication-of-phase-2a-results-for-mebufotenin-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4196","BK4585","BK4551","BK4539","GHRS","BK4535","BK4588","GH","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640154899","title":"GH Research Announces Publication of Phase 2a Postpartum Depression Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2640154899","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640154899?lang=en_us&edition=fundamental","pubTime":"2026-06-04 19:00","pubTimestamp":1780570800,"startTime":"0","endTime":"0","summary":"DUBLIN, June  04, 2026  (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS) today announced the publication of the full results from its Phase 2a trial in postpartum depression (PPD) and the acceptance","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/04/3306645/0/en/GH-Research-Announces-Publication-of-Phase-2a-Postpartum-Depression-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4551","BK4588","BK4196","BK4561","BK4535","BK4121","BK4585","GH","BK4530","PPD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640923733","title":"Crinetics and Leading Patient Groups Launch ‘Everyday Advocacy’ Initiative to Empower People Across Endocrine Disease Communities","url":"https://stock-news.laohu8.com/highlight/detail?id=2640923733","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640923733?lang=en_us&edition=fundamental","pubTime":"2026-06-03 04:05","pubTimestamp":1780430700,"startTime":"0","endTime":"0","summary":"Everyday Advocacy provides people living with endocrine and endocrine-related conditions with education, support, and tools to facilitate more impactful healthcare team interactions Steering committee","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/02/3305581/0/en/Crinetics-and-Leading-Patient-Groups-Launch-Everyday-Advocacy-Initiative-to-Empower-People-Across-Endocrine-Disease-Communities.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EMPW.U","GH","PTH","BK4535","BK4196","BK4551","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640149912","title":"Guardant Health Raised to Outperform From In-Line by Evercore ISI Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2640149912","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640149912?lang=en_us&edition=fundamental","pubTime":"2026-06-02 18:51","pubTimestamp":1780397460,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/GH/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 02, 2026 06:51 ET (10:51 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","BK4196","BK4585","GH","BK4551","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640912589","title":"Evercore ISI Upgrades Guardant Health to Outperform From In Line, Adjusts PT to $160 From $95","url":"https://stock-news.laohu8.com/highlight/detail?id=2640912589","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640912589?lang=en_us&edition=fundamental","pubTime":"2026-06-02 18:41","pubTimestamp":1780396916,"startTime":"0","endTime":"0","summary":"Guardant Health (GH) has an average rating of overweight and mean price target of $134.80, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from maj","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4535","BK4588","BK4585","BK4551","BK4196","GH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640911049","title":"Guardant Health Shares Rise 2.2% Premarket After Evercore Isi Upgrades Stock, Raises PT","url":"https://stock-news.laohu8.com/highlight/detail?id=2640911049","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640911049?lang=en_us&edition=fundamental","pubTime":"2026-06-02 18:06","pubTimestamp":1780394801,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nFWN42A01L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4588","GH","BK4551","BK4196","BK4585","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640591103","title":"Guardant Health Inc : Evercore Isi Raises to Outperform From in Line; Raises Target Price to $160 From $95","url":"https://stock-news.laohu8.com/highlight/detail?id=2640591103","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640591103?lang=en_us&edition=fundamental","pubTime":"2026-06-02 18:03","pubTimestamp":1780394608,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nFWN42A0EM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4535","BK4196","BK4585","BK4551","BK4588","GH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640916421","title":"Crinetics’ Paradigm-Shifting Portfolio and Pipeline on Display at ENDO 2026 with Six Presentations","url":"https://stock-news.laohu8.com/highlight/detail?id=2640916421","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640916421?lang=en_us&edition=fundamental","pubTime":"2026-06-02 16:55","pubTimestamp":1780390500,"startTime":"0","endTime":"0","summary":"Oral presentation features open label extension PALSONIFY (paltusotine) data, reinforcing its best-in-class potential in acromegaly following recent U.S. and E.U. approvals Two oral presentations of n","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/02/3304905/0/en/Crinetics-Paradigm-Shifting-Portfolio-and-Pipeline-on-Display-at-ENDO-2026-with-Six-Presentations.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0006061336.USD","BK4196","LU1571399168.USD","BK4175","LU1267930227.SGD","LU1267930813.SGD","SG9999001440.SGD","LU0072461881.USD","BK4588","PTH","BK4551","LU0792757196.USD","LU1880398471.USD","LU0154236417.USD","LU1267930490.SGD","LU0211328371.USD","BK4535","GH","CAH","LU0052756011.USD","LU0162691827.USD","LU1983299246.USD","BK4585","LU0128525689.USD","BK4183","ENDO","LU0889566641.SGD","LU0310800965.SGD","LU0310799852.SGD","LU0211327993.USD","LU1880398554.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640913560","title":"U.S. RESEARCH ROUNDUP-Edgewise Therapeutics, IBM, Rubrik","url":"https://stock-news.laohu8.com/highlight/detail?id=2640913560","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640913560?lang=en_us&edition=fundamental","pubTime":"2026-06-02 15:49","pubTimestamp":1780386551,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Edgewise Therapeutics, IBM, Rubrik June 2 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Edgewise","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nL4N42A0K5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GOU","TMHC","GOOX","ACRE","UNX","MANE","CAG","ORCL","FULC","ORCX","BRKR","GGLS","GH","RVMD","U","XFOR","HPE","IBM","GOOGL","CPB","ALGT","CHWY","ORCS","BTSG","GOOW","MOBI","BXMT","MLM","OCTV","GOOY","CIEN","PRAX","VMC","RBRK","ARXS","NAVN","SAIC","GOOP","SAIL","EW","BWA","ODTX","TTWO","LTH","SOC","MAC","ORCU","GGLL","EWTX","CZR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640962784","title":"Guardant Health assumed with an Outperform at Wolfe Research","url":"https://stock-news.laohu8.com/highlight/detail?id=2640962784","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640962784?lang=en_us&edition=fundamental","pubTime":"2026-06-02 04:54","pubTimestamp":1780347281,"startTime":"0","endTime":"0","summary":"Wolfe Research analyst Paige Chamberlain assumed coverage of Guardant Health (GH) with an Outperform rating and price target of $150, up from $120....","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/guardant-health-assumed-with-an-outperform-at-wolfe-research-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/guardant-health-assumed-with-an-outperform-at-wolfe-research-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4196","BK4585","BK4551","BK4535","BK4588","GH"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.guardanthealth.com","stockEarnings":[{"period":"1week","weight":-0.0004},{"period":"1month","weight":0.3597},{"period":"3month","weight":0.4781},{"period":"6month","weight":0.2835},{"period":"1year","weight":1.6271},{"period":"ytd","weight":0.2739}],"compareEarnings":[{"period":"1week","weight":-0.0296},{"period":"1month","weight":-0.0008},{"period":"3month","weight":0.0898},{"period":"6month","weight":0.0695},{"period":"1year","weight":0.2291},{"period":"ytd","weight":0.0808}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research. The company was incorporated in 2011 and is headquartered in Palo Alto, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.625,"avgChangeRate":0.071093},{"month":2,"riseRate":0.25,"avgChangeRate":0.034152},{"month":3,"riseRate":0.5,"avgChangeRate":-0.022808},{"month":4,"riseRate":0.375,"avgChangeRate":-0.022604},{"month":5,"riseRate":0.625,"avgChangeRate":0.118443},{"month":6,"riseRate":0.75,"avgChangeRate":0.072071},{"month":7,"riseRate":0.714286,"avgChangeRate":0.051469},{"month":8,"riseRate":0.571429,"avgChangeRate":0.08346},{"month":9,"riseRate":0.285714,"avgChangeRate":-0.065825},{"month":10,"riseRate":0.285714,"avgChangeRate":0.030366},{"month":11,"riseRate":0.75,"avgChangeRate":0.130427},{"month":12,"riseRate":0.5,"avgChangeRate":-0.066498}],"exchange":"NASDAQ","name":"Guardant Health Inc.","nameEN":"Guardant Health Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Guardant Health Inc.(GH),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Guardant Health Inc.(GH) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Guardant Health Inc.,GH,Guardant Health Inc.股票,Guardant Health Inc.股票老虎,Guardant Health Inc.股票老虎国际,Guardant Health Inc.行情,Guardant Health Inc.股票行情,Guardant Health Inc.股价,Guardant Health Inc.股市,Guardant Health Inc.股票价格,Guardant Health Inc.股票交易,Guardant Health Inc.股票购买,Guardant Health Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Guardant Health Inc.(GH),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Guardant Health Inc.(GH) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}